{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:42:46Z","timestamp":1788460966590,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s10557-008-6158-z","type":"journal-article","created":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T11:18:10Z","timestamp":1229599090000},"page":"103-105","source":"Crossref","is-referenced-by-count":2,"title":["Early Systemic Inflammatory Response to Drug-Eluting Stents Implantation: The Heart of the Difference?"],"prefix":"10.1007","volume":"23","author":[{"given":"Nuno M.","family":"Pires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,19]]},"reference":[{"key":"6158_CR1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1161\/01.ATV.0000037100.44766.5B","volume":"22","author":"FG Welt","year":"2002","unstructured":"Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769\u201376.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6158_CR2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1096\/fj.05-4634com","volume":"19","author":"PS Monraats","year":"2005","unstructured":"Monraats PS, Pires NM, Schepers A, et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J. 2005;19:1998\u20132004.","journal-title":"FASEB J"},{"key":"6158_CR3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.mehy.2007.01.090","volume":"69","author":"JJ Li","year":"2007","unstructured":"Li JJ, Li J, Nan JL, et al. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects. Med Hypotheses. 2007;69:1004\u20139.","journal-title":"Med Hypotheses"},{"key":"6158_CR4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ahj.2004.07.039","volume":"149","author":"N Saleh","year":"2005","unstructured":"Saleh N, Svane B, Jensen J, Hansson LO, Nordin M, Tornvall P. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 concentrations after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J. 2005;149:876\u201382.","journal-title":"Am Heart J"},{"key":"6158_CR5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.ehj.2004.04.027","volume":"25","author":"A Segev","year":"2004","unstructured":"Segev A, Kassam S, Buller CE, et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J. 2004;25:1029\u201335.","journal-title":"Eur Heart J"},{"key":"6158_CR6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ahj.2003.10.050","volume":"147","author":"AH Gomma","year":"2004","unstructured":"Gomma AH, Hirschfield GM, Gallimore JR Jr, Lowe GD, Pepys MB, Fox KM. Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J. 2004;147:1071\u20137.","journal-title":"Am Heart J"},{"key":"6158_CR7","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1053\/euhj.2000.2589","volume":"22","author":"WR Agema","year":"2001","unstructured":"Agema WR, Jukema JW, Pimstone SN, Kastelein JJ. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur Heart J. 2001;22:2058\u201374.","journal-title":"Eur Heart J"},{"key":"6158_CR8","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/CIRCULATIONAHA.105.536268","volume":"112","author":"PS Monraats","year":"2005","unstructured":"Monraats PS, Pires NM, Agema WR, et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005;112:2417\u201325.","journal-title":"Circulation"},{"key":"6158_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.gene.6364343","volume":"8","author":"PS Monraats","year":"2007","unstructured":"Monraats PS, Kurreeman FA, Pons D, et al. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun. 2007;8:44\u201350.","journal-title":"Genes Immun"},{"key":"6158_CR10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.fpc.0000220572.28585.5e","volume":"16","author":"PS Monraats","year":"2006","unstructured":"Monraats PS, de Vries F, de Jong LW, et al. Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention. Pharmacogenet Genomics. 2006;16:747\u201354.","journal-title":"Pharmacogenet Genomics"},{"key":"6158_CR11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","volume":"349","author":"JW Moses","year":"2003","unstructured":"Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315\u201323.","journal-title":"N Engl J Med"},{"key":"6158_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa032441","volume":"350","author":"GW Stone","year":"2004","unstructured":"Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221\u201331.","journal-title":"N Engl J Med"},{"key":"6158_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2004.01.021","volume":"99","author":"BL Hoeven van der","year":"2005","unstructured":"van der Hoeven BL, Pires NM, Warda HM, et al. Drug-eluting stents: results, promises and problems. Int J Cardiol. 2005;99:9\u201317.","journal-title":"Int J Cardiol"},{"key":"6158_CR14","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.amjcard.2005.12.037","volume":"97","author":"CM Gibson","year":"2006","unstructured":"Gibson CM, Karmpaliotis D, Kosmidou I, TIMI Study Group, et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol. 2006;97:1473\u20137.","journal-title":"Am J Cardiol"},{"key":"6158_CR15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cca.2008.06.021","volume":"396","author":"JJ Li","year":"2008","unstructured":"Li JJ, Qin XW, Yang XC, et al. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions. Clin Chim Acta. 2008;396:38\u201342.","journal-title":"Clin Chim Acta"},{"key":"6158_CR16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijcard.2006.07.073","volume":"119","author":"J Klitkou","year":"2007","unstructured":"Klitkou J, Jensen LO, Hansen HS, Thayssen P. High sensitive C-reactive protein and interleukin 6 are not related to neointimal hyperplasia in paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study. Int J Cardiol. 2007;119:114\u20136.","journal-title":"Int J Cardiol"},{"key":"6158_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11239-005-1378-6","volume":"19","author":"PB Gogo Jr","year":"2005","unstructured":"Gogo PB Jr, Schneider DJ, Watkins MW, Terrien EF, Sobel BE, Dauerman HL. Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis. 2005;19:87\u201392.","journal-title":"J Thromb Thrombolysis"},{"key":"6158_CR18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","volume":"370","author":"C Stettler","year":"2007","unstructured":"Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937\u201348.","journal-title":"Lancet"},{"key":"6158_CR19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/heart.89.2.218","volume":"89","author":"MR Bennett","year":"2003","unstructured":"Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart. 2003;89:218\u201324.","journal-title":"Heart"},{"key":"6158_CR20","doi-asserted-by":"crossref","unstructured":"Li JJ, Yan HB, Xiang XP, et al. Comparison of changes in early inflammatory markers between sirolimus-and paclitaxel-eluting stent implantation. Cardiovasc Drugs Ther. 2009;23 (this issue).","DOI":"10.1007\/s10557-008-6149-0"},{"key":"6158_CR21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/hrt.2006.102244","volume":"93","author":"NM Pires","year":"2007","unstructured":"Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 2007;93:922\u20137.","journal-title":"Heart"},{"key":"6158_CR22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/CIRCULATIONAHA.104.508937","volume":"112","author":"AV Finn","year":"2005","unstructured":"Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270\u20138.","journal-title":"Circulation"},{"key":"6158_CR23","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.amjcard.2005.07.042","volume":"96","author":"JY Kim","year":"2005","unstructured":"Kim JY, Ko YG, Shim JY, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol. 2005;96:1384\u20138.","journal-title":"Am J Cardiol"},{"key":"6158_CR24","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.amjcard.2005.11.060","volume":"97","author":"A Gaspardone","year":"2006","unstructured":"Gaspardone A, Versaci F, Tomai F, et al. C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol. 2006;97:1311\u20136.","journal-title":"Am J Cardiol"},{"key":"6158_CR25","doi-asserted-by":"crossref","unstructured":"Kang WC, Moon CI, Ahn TH, Shin EK. Comparison of inflammatory markers and angiographic outcomes after implantation of rapamycin and paclitaxel-eluting stents. Heart. 2008. doi: 10.1136\/hrt.2008.153114","DOI":"10.1136\/hrt.2008.153114"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-008-6158-z.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T08:33:44Z","timestamp":1557995624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-008-6158-z"}},"subtitle":["Editorial to: \u201cComparison of Changes in Early Inflammatory Markers Between Sirolimus- and Paclitaxel-Eluting Stent Implantation\u201d by Li et al."],"short-title":[],"issued":{"date-parts":[[2008,12,19]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["6158"],"URL":"https:\/\/doi.org\/10.1007\/s10557-008-6158-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,19]]}}}